Resiquimod (GMP)-Get quote

Description

Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages[1][2][3].–Applications-COVID-19-immunoregulation-Formula-C17H22N4O2-Citation–References-[1]Bayik D, et al. Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages. Front Immunol. 2018 Mar 26;9:608. |[2]Preisendörfer S, et al. FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. Cells. 2022 Apr 14;11(8):1341. |[3]Lee M, et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234-40. -CASNumber-144875-48-9-MolecularWeight-314.38-Compound Purity–SMILES-OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N-Research_Area-Cancer; Inflammation/Immunology-Solubility-10 mM in DMSO-Target-Toll-like Receptor (TLR)-Isoform-TLR7;TLR8-Pathway-Immunology/Inflammation-MCE Product type-GMP Small Molecules